Company news
Arcus Biosciences, Inc. (NYSE:RCUS) news
Every Arcus Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advance...
July 22, 2026
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kid...
July 22, 2026
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
July 21, 2026
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bis...
June 3, 2026
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
May 5, 2026
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
April 21, 2026
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
February 25, 2026
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney C...
February 23, 2026
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
February 11, 2026
Arcus Biosciences Announces New Employment Inducement Grants
January 26, 2026
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
January 7, 2026
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunolog...
December 12, 2025
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
November 18, 2025
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
October 30, 2025
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
October 30, 2025
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
October 28, 2025
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
October 19, 2025
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatmen...
October 12, 2025
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
October 6, 2025
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
September 2, 2025
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
August 20, 2025
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
August 6, 2025
Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer
July 10, 2025
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Con...
June 1, 2025
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
May 6, 2025
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025...
April 23, 2025
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
April 22, 2025
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
February 25, 2025
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common ...
February 18, 2025
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
February 18, 2025
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
February 15, 2025